+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cervical Cancer - Pipeline Review, H2 2019

  • ID: 4894233
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 1380 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Astex Pharmaceuticals Inc
  • CZ BioMed Corp
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Puma Biotechnology Inc
  • MORE
Cervical Cancer - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2019, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 77, 68, 4, 37, 9 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 2, 12 and 4 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Astex Pharmaceuticals Inc
  • CZ BioMed Corp
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Puma Biotechnology Inc
  • MORE
Introduction
Cervical Cancer - Overview
Cervical Cancer - Therapeutics Development
Cervical Cancer - Therapeutics Assessment
Cervical Cancer - Companies Involved in Therapeutics Development
Cervical Cancer - Drug Profiles
Cervical Cancer - Dormant Projects
Cervical Cancer - Discontinued Products
Cervical Cancer - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Cervical Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Cervical Cancer - Pipeline by 3SBio Inc, H2 2019
Cervical Cancer - Pipeline by Aadi Bioscience Inc, H2 2019
Cervical Cancer - Pipeline by AbbVie Inc, H2 2019
Cervical Cancer - Pipeline by Abion Inc, H2 2019
Cervical Cancer - Pipeline by Abivax SA, H2 2019
Cervical Cancer - Pipeline by Admedus Ltd, H2 2019
Cervical Cancer - Pipeline by Advaxis Inc, H2 2019
Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2019
Cervical Cancer - Pipeline by Agenus Inc, H2 2019
Cervical Cancer - Pipeline by Akeso Biopharma Inc, H2 2019
Cervical Cancer - Pipeline by Almac Discovery Ltd, H2 2019
Cervical Cancer - Pipeline by Altor Bioscience LLC, H2 2019
Cervical Cancer - Pipeline by amcure GmbH, H2 2019
Cervical Cancer - Pipeline by Andes Biotechnologies, H2 2019
Cervical Cancer - Pipeline by Anew Oncology Inc, H2 2019
Cervical Cancer - Pipeline by AntiCancer Inc, H2 2019
Cervical Cancer - Pipeline by Apimeds Inc, H2 2019
Cervical Cancer - Pipeline by Apollomics Inc, H2 2019
Cervical Cancer - Pipeline by Apotex Inc, H2 2019

List of Figures
Number of Products under Development for Cervical Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3SBio Inc
  • Aadi Bioscience Inc
  • AbbVie Inc
  • Abion Inc
  • Abivax SA
  • Admedus Ltd
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Agenus Inc
  • Akeso Biopharma Inc
  • Almac Discovery Ltd
  • Altor Bioscience LLC
  • amcure GmbH
  • Andes Biotechnologies
  • Anew Oncology Inc
  • AntiCancer Inc
  • Apimeds Inc
  • Apollomics Inc
  • Apotex Inc
  • Asana BioSciences LLC
  • Ascenta Therapeutics Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd
  • Beijing Neoantigen Biotechnology Co Ltd
  • Beijing Recreation Guards Biotechnology Co Ltd
  • Biocad
  • BIOCND Inc
  • BioIntegrator Ltd
  • Bioleaders Corp
  • Biomics Biotechnologies Co Ltd
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Celleron Therapeutics Ltd
  • Cellestia Biotech AG
  • Cellid Co Ltd
  • Centus Biotherapeutics Ltd
  • Changchun Bcht Biotechnology Co Ltd
  • Chineo Med Beijing Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Clovis Oncology Inc
  • Convert Pharmaceuticals SA
  • Corvus Pharmaceuticals Inc
  • Cotinga Pharmaceuticals Inc
  • Cue Biopharma Inc
  • Cytocom Inc
  • CytomX Therapeutics Inc
  • CZ BioMed Corp
  • Daewon Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • DelMar Pharmaceuticals Inc
  • EirGenix Inc
  • Eli Lilly and Co
  • Epygen Biotech Pvt Ltd
  • Etna Biotech Srl
  • Etubics Corp
  • Eubiologics Co Ltd
  • Exelixis Inc
  • EyeGene Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Flow Pharma Inc
  • Forbius
  • Fujifilm Holdings Corp
  • GamaMabs Pharma SA
  • Gene Techno Science Co Ltd
  • Genentech Inc
  • Genetic Immunity Inc
  • Genexine Inc
  • Genmab A/S
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glycostem Therapeutics BV
  • GO Therapeutics Inc
  • Gradalis Inc
  • Hamlet Pharma AB
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Hefei Ruichengsheng Biotechnology Co Ltd
  • Hookipa Pharma Inc
  • Immune Therapeutics Inc
  • Immunitor Inc
  • Immunomedics Inc
  • IMV Inc
  • Incyte Corp
  • Innate Pharma SA
  • Innovene
  • Innovent Biologics Inc
  • InSight Biopharmaceuticals Ltd
  • Invectys SA
  • Iovance Biotherapeutics Inc
  • ISA Pharmaceuticals BV
  • Jiangsu Alphamab Biopharmaceuticals Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Komipharm International Co Ltd
  • Kymab Ltd
  • Medical Guidance Systems LLC
  • Merck & Co Inc
  • Merck KGaA
  • MicroQuin Ltd
  • Midissia Therapeutics Inc
  • Molecular Partners AG
  • Mundipharma EDO GmbH
  • Mycenax Biotech Inc
  • NeoTX Therapeutics Ltd
  • Newish Technology Beijing Co Ltd
  • Novartis AG
  • Noyan Pajouhan Biopharma
  • OncoMed Pharmaceuticals Inc
  • Onconova Therapeutics Inc
  • OncoSec Medical Inc
  • Ono Pharmaceutical Co Ltd
  • Oxford Vacmedix UK Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • PharmAbcine Inc
  • Phoenix Life Sciences International Ltd
  • PI Therapeutics Ltd
  • Plus Therapeutics Inc
  • Potenza Therapeutics Inc
  • Prestige BioPharma Pte Ltd
  • Puma Biotechnology Inc
  • RAPT Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Rexahn Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • Samyang Holdings Corp
  • Sanofi
  • Savoy Pharmaceuticals Inc
  • Selecta Biosciences Inc
  • Shanghai Bovax Biotechnology Co Ltd
  • Shanghai Henlius Biotech Inc
  • Shanghai Institute of Biological Products Co Ltd
  • Shanghai Zerun Biotechnology Co Ltd
  • Shantha Biotechnics Pvt Ltd
  • Shattuck Labs Inc
  • Siam Bioscience Co Ltd
  • Sierra Oncology Inc
  • SK Bioscience
  • Sorrento Therapeutics Inc
  • Spring Bank Pharmaceuticals Inc
  • SQZ Biotechnologies Co
  • Starpharma Holdings Ltd
  • Suzhou Stainwei Biotech Inc
  • Synermore Biologics Co Ltd
  • TCRCure Biotech Co Ltd
  • Tessa Therapeutics Pte Ltd
  • Theralase Technologies Inc
  • Theravectys SA
  • THEVAX Genetics Vaccine USA Inc
  • Transgene SA
  • Turnstone Biologics Inc
  • Vectorite Biomedical Inc
  • ViciniVax BV
  • Vir Biotechnology Inc
  • Virion Therapeutics LLC
  • Virometix AG
  • VLP The Vaccines Company SL
  • Xencor Inc
  • Xiamen Innovax Biotech Co Ltd
  • Zeria Pharmaceutical Co Ltd
  • Zhejiang Yangshengtang Biotech Co Ltd
  • Zymeworks Inc
Note: Product cover images may vary from those shown
Adroll
adroll